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Like rheumatoid arthritis, ankylosing spondylitis (AS) is also an inflammatory disease associated with accelerated atherosclerosis
and the presence of metabolic syndrome (MeS) features. AS patients often display osteoporosis as well as new bone formation.
Insulin-like growth factor 1 (IGF-1) is a protein involved in both inflammation and bone metabolism. In the present study we
assessed whether disease activity, systemic inflammation, MeS features, adipokines, and biomarkers of endothelial activation
were associated with IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) levels in a series of 30 nondiabetic AS
patients without CV disease undergoing TNF-𝛼 antagonist-infliximab therapy. All determinations were made in the fasting state,
immediately before an infliximab infusion. Although no association of IGF-1 and IGFBP-3 levels with angiopoietin-2 or osteopontin
was found, an inverse correlation between IGF-1 levels and asymmetric dimethylarginine (ADMA), an endogenous endothelial
nitric oxide synthase inhibitor that impairs nitric oxide production and secretion promoting endothelial dysfunction, was found
(𝑟 = −0.397; 𝑃 = 0.04). However, no significant association was found between IGF-1 and IGFBP-3 levels and disease activity,
systemic inflammation, metabolic syndrome features, or adipokines. In conclusion, in nondiabetic patients with AS undergoing
periodic anti-TNF-𝛼 therapy, IGF-1 and ADMA are inversely correlated.
1. Introduction
Like rheumatoid arthritis, ankylosing spondylitis (AS) is
also a chronic inflammatory rheumatic disease in which an
increased incidence of cardiovascular (CV) mortality due
to accelerated atherosclerosis has been reported [1]. Besides
the typical manifestations of AS such as synovitis, enthesitis,
uveitis, and new bone formation [2], AS patients often display
a dysregulation of adipokines andmetabolic syndrome (MeS)
features (obesity, dyslipidemia, hypertension, and alterations
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in glucose metabolism, including insulin resistance (IR))
[3, 4]. Regarding therapeutic strategies for the treatment of
AS, anti-TNF-𝛼 therapy was found to be effective to treat
patients with this disease [5–7]. Anti-TNF-𝛼 agents lead to
a suppression of inflammation and thus to a reduction of
disease activity, as well as to an improvement of endothelial
function in AS patients [8, 9]. This is the reason why the
assessment of new potential CV risk biomarkers and the
influence of anti-TNF-𝛼 therapy on them could shed light on
the biologic mechanisms of these biologic agents associated
with atherosclerosis in AS patients.
Our group has previously evaluated the involvement of
metabolic syndrome (MeS) related biomarkers, adipokines,
and biomarkers of endothelial cell activation and inflam-
mation in a series of nondiabetic AS patients on period-
ical treatment with the anti-TNF-𝛼 monoclonal antibody,
infliximab. Regarding MeS related biomarkers, we disclosed
a link between IR and serum ghrelin concentration in our
series of AS patients [10], as well as an association between
retinol binding protein-4 (RBP-4) and MeS features such
as IR and systolic blood pressure [11]. We also assessed
the potential association between different adipokines and
clinical and demographic features of AS. In this regard, we
found a positive correlation between adiponectin serum lev-
els and insulin sensitivity (IS), suggesting that low circulating
adiponectin concentrationsmay be associatedwithmetabolic
abnormalities that promote CV disease in AS [12]. We also
observed an association between adiponectin levels and the
presence of involvement or synovitis and/or enthesitis in
other peripheral joints [12]. Finally, we disclosed a corre-
lation between visfatin levels and IR [13]. With regard to
biomarkers of endothelial cell activation and inflammation,
we observed a link between asymmetric dimethylarginine
(ADMA) concentration and some features of MeS [14], an
association between angiopoietin-2 (Angpt-2) serum levels
and the age at the onset of symptoms of AS and disease
duration [15], and also a positive correlation between serum
levels of osteopontin (OPN) and Angpt-2 [16]. Furthermore,
we also disclosed an independent correlation between osteo-
protegerin (OPG) and ADMA [17] and an inverse correlation
between TNF-related apoptosis-inducing ligand (TRAIL)
and IS and resistin [18].
Insulin-like growth factor 1 (IGF-1) is produced by many
tissues, mainly by the liver, and it is involved in biologic
processes such as osteoblasts growth and differentiation [19].
IGF-1 is also involved in the modulation of immunity and
inflammation [20]. Circulating IGF-1 levels are under the
control of growth hormone (GH). In addition, IGF-1’s effects
are modulated by members of the insulin-like growth factor
binding proteins (IGFBP) [21]. Insulin-like growth factor
binding protein-3 (IGFBP-3) is a 264-amino acid peptide
produced by the liver. It is the most abundant of a group of
IGFBP that transport and control bioavailability and half-life
of IGF, in particular IGF-1 [21].
Even if new bone formation is a typical feature of AS,
these patients can also display bone loss, leading to an
increased rate of vertebral compression fractures [22]. In this
regard, IGF-1 has been associated with osteoporosis, being
reported decreased levels of this protein in patients with AS
[23, 24]. In line with this, Johansson et al. showed that IGF-1
administration promoted bone formation in osteoporotic
patients [25]. Regarding inflammation, previous studies have
shown that IGF-1 is inversely correlated to erythrocyte
sedimentation rate (ESR), a marker of inflammation [26].
Taking all these considerations into account, in the
present study we aimed to assess potential associations
between disease activity, systemic inflammation, adipokines
and biomarkers of endothelial activation, and MeS features
with circulating IGF-1 and IGFBP-3 levels in nondiabetic AS
patients undergoing infliximab therapy.
2. Patients and Methods
2.1. Patients. We assessed a series of 30 patients with AS
attending hospital outpatient clinics seen over 14 months
(January 2009 to March 2010), who fulfilled the modified
NewYork diagnostic criteria for AS [27].Theywere treated by
the same group of rheumatologists and were recruited from
the Hospital Lucus Augusti (Xeral-Calde), Lugo, Spain.
AS patients on treatment with infliximab seen during the
period of recruitment with diabetes mellitus or with plasma
glucose levels greater than 110mg/dL were excluded. None
of the patients included in the study had hyperthyroidism or
renal insufficiency. Also, patients seen during the recruitment
period who had experienced CV events, including ischemic
heart disease, heart failure, cerebrovascular accidents, or
peripheral arterial disease, were excluded. Patients were
diagnosed as having hypertension if blood pressure was
>140/90mmHg or they were taking antihypertensive agents.
Patients were considered to have dyslipidemia if they had
hypercholesterolemia and/or hypertriglyceridemia (defined
as diagnosis of hypercholesterolemia or hypertriglyceridemia
by the patients’ family physicians, or total cholesterol and/or
triglyceride levels in fasting plasma were >220mg/dL and
>150mg/dL, resp.). Obesity was defined if body mass index
(BMI) (calculated as weight in kilograms divided by height
in squared meters) was greater than 30.
In all cases treatment with the anti-TNF-𝛼 monoclonal
antibody, infliximab, was started because of active disease. All
patients included in the current study had begun treatment
with NSAIDs immediately after the disease diagnosis. All of
them were still being treated with these drugs at the time
of the study. At the time of this study most patients were
on treatment with naproxen: 500–1000mg/d. Although the
2010 updated recommendations facilitate initiation of TNF-
𝛼 blockers in AS and only ask for 2 NSAIDs with a minimum
total treatment period of 4 weeks [28], for the initiation
of anti-TNF-𝛼 therapy in these series of patients recruited
between January 2009 andMarch 2010, they had to be treated
with at least 3NSAIDs prior to the onset of infliximab therapy.
A clinical index of disease activity (Bath ankylosing
spondylitis disease activity index—BASDAI—range of 0 to
10) [29] was evaluated in all patients at the time of the
study. Clinical information on hip involvement, history of
synovitis in other peripheral joints and peripheral enthe-
sitis, history of anterior uveitis, presence of syndesmo-
phytes, and HLA-B27 status (typed by cell cytotoxicity) was
assessed. Moreover, C-reactive protein (CRP) by a latex
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immunoturbidity method, ESR-Westergren, serum glucose,
total cholesterol, high-density lipoprotein (HDL) cholesterol
and low-density lipoprotein (LDL) cholesterol, and triglyc-
erides (fasting overnight determinations) were assessed in all
the patients at the time of the study.
The characteristics of the AS patients included in this
study have been previously described [18]. Since at that
time all patients were undergoing periodical treatment with
the anti-TNF-𝛼 monoclonal antibody, infliximab (median
duration of periodical treatment with this biologic agent: 23
months), the mean BASDAI ± standard deviation (SD) was
only 2.94 ± 2.11.
The local institutional committee approved anti-TNF-𝛼
therapy.Also, patients gave informed consent to participate in
this study. This study was not supported by a pharmaceutical
drug company.
2.2. Study Protocol. All determinations were made in the
fasting state, prior to an infliximab infusion. Blood samples
were taken at 0800 hours for determination of the ESR (West-
ergren), CRP (latex immunoturbidimetry), lipids (enzymatic
colorimetry), plasma glucose, and serum insulin (DPC,
Dipesa, Los Angeles, CA, USA). As previously described,
insulin resistance was estimated by the homeostasis model
assessment of insulin resistance (HOMA-IR) using the for-
mula insulin (𝜇U/mL) × glucose (mmoL/L) ÷ 22.57 [30].
A commercial ELISA kit was used to measure plasma IGF-
1 and IGFBP-3 levels (R&D Systems, DG100 and DGB300;
assay sensitivity = 0.026 and 0.05 ng/mL; intra- and interassay
coefficients of variation were <4% and <8% for IFG-1 ELISA
kit and<4% and<6.6% for IFGBP-3 ELISA kit, resp.) (Abing-
don, UK) according to the manufacturer’s instructions. Total
plasma adiponectin and OPG levels, serum resistin, leptin,
visfatin, apelin, Angpt-2, ADMA, gelsolin, ghrelin, OPN,
RBP-4, and TRAIL levels were determined by ELISA as
previously described [10–18, 31, 32].
2.3. Statistical Analyses. Variables were expressed as mean ±
SD or percentages. Correlation between IGF-1 and IGFBP-3
plasma levels with selected continuous variables was per-
formed adjusting for age at the time of the study, sex, and
classic CV risk factors via estimation of the Pearson partial
correlation coefficient (𝑟).
The associations between characteristics and plasma
IGF-1 and IGFBP-3 concentrations were assessed by Stu-
dent’s paired 𝑡-test. Differences in IGF-1 and IGFBP-3 levels
between men and women and patients with hypertension or
not were assessed by Mann-Whitney 𝑈 test.
Two-sided 𝑃 values ≤ 0.05 were considered to indicate
statistical significance. Analyses were performed using Stata
12/SE (StataCorp, College Station, TX).
3. Results
3.1. Relationship of IGF-1 and IGFBP-3 Levels with Disease
Activity and Clinical Features. No difference was disclosed
between circulating IGF-1 and IGFBP-3 and disease activity
parameters, such as disease duration, BASDAI, or VAS
spinal pain at the time of the study (Table 1). Similarly, we
did not observe any difference in IGF-1 or IGFBP-3 levels
when patients were stratified according to history of anterior
uveitis, presence of syndesmophytes, hip involvement or
synovitis in other peripheral joints, peripheral enthesitis, and
HLA-B27 status (data not shown).
3.2. Relationship of Demographic Features, Inflammation,
Adiposity, and Adipokines with Circulating IGF-1 and IGFBP-
3 Levels. We did not observe any significant association
between IGF-1 and IGFBP-3 plasma levels and age at the onset
of symptoms, BMI, CRP, or ESR at the time of the study
and at the time of disease diagnosis (Table 1). Likewise, no
association with any of the adipokines studied was observed
(Table 2). Additionally, no difference in IGF-1 and IGFBP-3
concentration between men and women was observed (data
not shown).
3.3. Relationship of IGF-1 and IGFBP-3 Levels with MeS Fea-
tures OtherThan Adiposity. IGF-1 and IGFBP-3 plasma levels
did not show any statistical correlation with systolic or dias-
tolic blood pressure, total cholesterol, LDL cholesterol, HDL
cholesterol, triglycerides, serum glucose levels, insulin sensi-
tivity (QUICKI), or insulin resistance (HOMA-IR) (Tables 1
and 2). Similarly, we did not find a correlation between IGF-1
and IGFBP-3 concentration and MeS-associated biomarkers
such as ghrelin or RBP-4 (Table 2). Besides, when patients
were stratified according to the presence or absence of arterial
hypertension, no significant differences in IGF-1 and IGFBP-
3 plasma levels were seen (not shown).
3.4. Relationship of IGF-1 and IGFBP-3 Plasma Levels with
Biomarkers of Endothelial Cell Activation and Atherosclerosis.
We found an inverse correlation between IGF-1 and ADMA
levels (𝑟 = −0.397; 𝑃 = 0.04) (Table 2). However, no
association was observed between IGFBP-3 and ADMA
levels. Likewise, no correlation was observed between IGF-1
and IGFBP-3 and Angpt-2 or OPN (Table 2).
4. Discussion
The present study discloses an inverse correlation between
levels of IGF-1 and ADMA, a biomarker of endothelial cell
activation, in AS patients under periodic treatment with
anti-TNF-𝛼 therapy. Our results are in keeping with those
obtained by Setola et al., who also reported that IGF-1 and
ADMA levels were negatively associated after six months of
growth hormone treatment [33].
Previous in vivo studies demonstrate that IGF-1 stimula-
tion induces an increase in endothelial nitric oxide synthase
(eNOS) activity, with the ensuing increase of nitric oxide
(NO) [34]. Taking into account that NO is a key factor for
the maintenance of vascular homeostasis, this could lead to
an improvement of endothelial function. In contrast, ADMA
(an endogenous eNOS synthase inhibitor) impairs NO pro-
duction and secretion [14]. Consequently, increased levels
of ADMA could be detrimental for endothelial function
and have indeed been associated with subclinical markers
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Table 1: Partial correlation of plasma IGF-1 and IGFBP-3 with clinical characteristics and routine laboratory parameters prior to an
infliximab infusion, adjusting by age at the time of the study, sex, and classic cardiovascular risk factors (dyslipidemia, smoking, obesity,
and hypertension) in 30 nondiabetic patients with ankylosing spondylitis.
Variable IGF-1 IGFBP-3
𝑟 𝑃 𝑟 𝑃
Clinical characteristics
Age at the onset of symptoms −0.274 0.17 0.111 0.58
Disease duration∗ 0.353 0.07 −0.029 0.89
BMI∗ −0.032 0.87 −0.191 0.34
Systolic blood pressure∗ 0.245 0.22 0.196 0.33
Diastolic blood pressure∗ −0.012 0.95 0.192 0.34
BASDAI∗ −0.044 0.83 −0.006 0.98
VAS spinal pain∗ −0.119 0.55 0.169 0.40
Routine laboratory parameters
ESR∗ (natural-log-transformed) −0.104 0.61 0.174 0.39
CRP∗ (natural-log-transformed) −0.045 0.82 −0.111 0.58
ESR∗∗ (natural-log-transformed) −0.033 0.87 0.108 0.59
CRP∗∗ (natural-log-transformed) −0.008 0.97 −0.132 0.51
Total cholesterol∗ (natural-log-transformed) −0.030 0.88 0.020 0.92
HDL cholesterol∗ (natural-log-transformed) −0.102 0.61 −0.138 0.49
LDL cholesterol∗ (natural-log-transformed) 0.071 0.73 0.041 0.84
Atherogenic index∗ (total cholesterol/HDL) 0.102 0.62 0.161 0.43
Triglycerides∗ (natural-log-transformed) −0.084 0.68 0.173 0.39
Serum glucose∗ (natural-log-transformed) 0.054 0.79 −0.225 0.26
∗At the time of the study. ∗∗At the time of disease diagnosis.
BASDAI: Bath ankylosing spondylitis disease activity index; BMI: body mass index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HDL:
high-density lipoprotein; IGF-1: insulin-like growth factor 1; IGFBP-3: insulin-like growth factor binding protein-3; LDL: low-density lipoprotein; VAS: visual
analogue scale.
Table 2: Partial correlation of plasma IGF-1 and IGFBP-3 with metabolic parameters at baseline, prior to an infliximab infusion, adjusting by
age at the time of the study, sex, and classic cardiovascular risk factors (dyslipidemia, smoking, obesity, and hypertension) in 30 nondiabetic
patients with ankylosing spondylitis.
Variable IGF-1 IGFBP-3
𝑟 𝑃 𝑟 𝑃
HOMA-IR at time 0∗ 0.273 0.17 0.052 0.80
QUICKI at time 0∗ −0.280 0.16 −0.116 0.56
Resistin at time 0 0.341 0.12 −0.270 0.22
Adiponectin at time 0 −0.215 0.29 0.158 0.44
Leptin at time 0 0.313 0.12 −0.310 0.12
Visfatin at time 0 −0.074 0.72 0.068 0.74
Angpt-2 at time 0 0.080 0.69 0.274 0.17
Apelin at time 0 −0.005 0.98 0.237 0.23
ADMA at time 0 −0.397 0.04 −0.346 0.08
Ghrelin at time 0 −0.175 0.39 −0.327 0.10
Gelsolin at time 0 0.148 0.46 0.180 0.37
OPN at time 0 0.168 0.40 0.004 0.99
RBP-4 at time 0 0.339 0.08 0.053 0.79
OPG at time 0 −0.049 0.81 0.063 0.76
TRAIL at time 0 0.109 0.59 0.122 0.54
IGFBP-3 at time 0 0.163 0.42 — —
IGF-1 at time 0 — — 0.163 0.42
∗At the time of the study.
ADMA: asymmetric dimethylarginine; Angpt-2: angiopoietin-2; HOMA-IR: homeostasis model assessment of insulin resistance; IGF-1: insulin-like growth
factor 1; IGFBP-3: insulin-like growth factor binding protein-3; OPG: osteoprotegerin; OPN: osteopontin; QUICKI: quantitative insulin sensitivity check index;
RBP-4: retinol binding protein-4; TRAIL: TNF-related apoptosis-inducing ligand. Significant results are highlighted in bold.
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of atherosclerosis and cardiovascular disease [35, 36]. In
accordance with these data, Ji et al. recently performed a
study to assess the potential relationship between vascular
endothelial function in hypercholesterolemic patients and
serum IGF-1 and ADMA levels. They found that IGF-1 levels
positively correlated with flow-mediated arterial diastolic
function (FMD), while ADMA levels showed a negative
correlation with FMD [37]. These results further support the
idea that IGF-1 is involved in vascular endothelial function.
In previous studies performed in our cohort of AS
patients undergoing anti-TNF-𝛼 therapy, we found that
ADMA levels were associated with features of MeS, such as
hypertension [14]. Even if in the present study we did not
observe any correlation between IGF-1 and MeS features, we
did find an inverse correlation of IFG-1 andADMA. Probably,
as a result of long-term anti-TNF-𝛼 treatment (median = 23
months), ADMA levels were decreased in our AS patients,
while IGF-1 levels were increased. In keeping with these
observations, an inverse correlation betweenTNF-𝛼 and IGF-
1 levels was disclosed in AS patients by Lange et al. [38]. In
addition, Briot et al. showed an increase in IGF-1 levels in
AS patients being treated with infliximab [39].Therefore, this
could be a potentialmechanismbywhich anti-TNF-𝛼 therapy
improves endothelial function in AS patients.
It is important to highlight that this is a well-controlled
population, displaying low disease activity levels at the time
of the study as a result of long-term anti-TNF-𝛼 therapy [8].
Therefore, this may explain the lack of association of IGF-1
and IGFBP-3withmost of the variables included in this study.
5. Conclusion
We can conclude that, in nondiabetic patients with AS
undergoing periodic anti-TNF-𝛼 therapy, IGF-1 and ADMA
are inversely correlated.
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[4] F. Genre, R. López-Mej́ıas, J. A. Miranda-Filloy et al., “Adipok-
ines, biomarkers of endothelial activation, and metabolic syn-
drome in patients with ankylosing spondylitis,” Biomedical
Research International, vol. 2014, Article ID 860651, 11 pages,
2014.
[5] S. D’Angelo, C. Palazzi, F. Cantini et al., “Etanercept in spondy-
loarthropathies. Part II: safety and pharmacoeconomic issues,”
Clinical and Experimental Rheumatology, vol. 29, no. 5, pp. 865–
870, 2011.
[6] C. Palazzi, S. D'Angelo, F. Cantini et al., “Etanercept in spondy-
loarthropathies, part I: current evidence of efficacy,”Clinical and
Experimental Rheumatology, vol. 29, no. 5, pp. 858–864, 2011.
[7] F. Heldmann, J. Brandt, I. E. van derHorst-Bruinsma et al., “The
European ankylosing spondylitis infliximab cohort (EASIC): a
European multicentre study of long-term outcomes in patients
with ankylosing spondylitis treated with infliximab,” Clinical
and Experimental Rheumatology, vol. 29, no. 4, pp. 672–680,
2011.
[8] J. S. Smolen and P. Emery, “Infliximab: 12 years of experience,”
Arthritis Research andTherapy, vol. 13, article S2, no. 1, 2011.
[9] A. Syngle, K. Vohra, A. Sharma, and L. Kaur, “Endothelial
dysfunction in ankylosing spondylitis improves after tumor
necrosis factor-𝛼 blockade,” Clinical Rheumatology, vol. 29, no.
7, pp. 763–770, 2010.
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ankylosing spondylitis and low disease activity because of anti-
TNF-alpha therapy have higher TRAIL levels than controls: a
potential compensatory effect,”Mediators of Inflammation, vol.
2014, Article ID 798060, 6 pages, 2014.
[19] E. Toussirot, N. U. Nguyen, G. Dumoulin, J. Regnard, and D.
Wendling, “Insulin-like growth factor-I and insulin-like growth
factor binding protein-3 serum levels in ankylosing spondylitis,”
TheBritish Journal of Rheumatology, vol. 37, no. 11, pp. 1172–1176,
1998.
[20] V. H. Heemskerk, M. A. Daemen, and W. A. Buurman,
“Insulin-like growth factor-1 (IGF-1) and growth hormone
(GH) in immunity and inflammation,” Cytokine & Growth
Factor Reviews, vol. 10, no. 1, pp. 5–14, 1999.
[21] P. Delafontaine, Y.-H. Song, and Y. Li, “Expression, regulation,
and function of IGF-1, IGF-1R, and IGF-1 binding proteins
in blood vessels,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 24, no. 3, pp. 435–444, 2004.
[22] E. Toussirot and D. Wendling, “Osteoporosis in ankylosing
spondylitis,” Presse Medicale, vol. 25, no. 15, pp. 720–724, 1996.
[23] C. Wuster, W. F. Blum, S. Schlemilch, M. B. Ranke, and R.
Ziegler, “Decreased serum levels of insulin-like growth factors
and IGF binding protein 3 in osteoporosis,” Journal of Internal
Medicine, vol. 234, no. 3, pp. 249–255, 1993.
[24] S. Ljunghall, A. G. Johansson, P. Burman, O. Kampe, E. Lindh,
and F. A. Karlsson, “Low plasma levels of insulin-like growth
factor 1 (IGF-1) in male patients with idiopathic osteoporosis,”
Journal of Internal Medicine, vol. 232, no. 1, pp. 59–64, 1992.
[25] A. G. Johansson, E. Lindh, W. F. Blum, G. Kollerup, O. H.
Sørensen, and S. Ljunghall, “Effects of growth hormone and
insulin-like growth factor I in men with idiopathic osteoporo-
sis,” Journal of Clinical Endocrinology and Metabolism, vol. 81,
no. 1, pp. 44–48, 1996.
[26] R. Cimaz, R. Rusconi, B. Cesana et al., “A multicenter study
on insulin-like growth factor-I serum levels in children with
chronic inflammatory diseases,” Clinical and Experimental
Rheumatology, vol. 15, no. 6, pp. 691–696, 1997.
[27] S. van der Linden, H. A. Valkenburg, and A. Cats, “Evaluation
of diagnostic criteria for ankylosing spondylitis: a proposal for
modification of the New York criteria,” Arthritis and Rheuma-
tism, vol. 27, no. 4, pp. 361–368, 1984.
[28] D. van der Heijde, J. Sieper, W. P. Maksymowych et al., “2010
Update of the international ASAS recommendations for the
use of anti-TNF agents in patients with axial spondyloarthritis,”
Annals of the Rheumatic Diseases, vol. 70, no. 6, pp. 905–908,
2011.
[29] S. Garrett, T. Jenkinson, L. G. Kennedy, H. Whitelock, P.
Gaisford, and A. Calin, “A new approach to defining disease
status in ankylosing spondylitis: the bath ankylosing spondylitis
disease activity index,”The Journal of Rheumatology, vol. 21, no.
12, pp. 2286–2291, 1994.
[30] J. A. Miranda-Filloy, J. Llorca, B. Carnero-López, C. González-
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